Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for posttraumatic stress disorder (PTSD). For more information, please visit www.recoverystudy.com or www.clinicaltrials.gov (NCT03841773).

Financial Info
: Financials

Financials

v3.19.3
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)
$ in Thousands
Sep. 30, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 10,024 $ 25,034
Prepaid expenses and other 1,529 1,022
Total current assets 11,553 26,056
Property and equipment, net 34 43
Right to use assets, net 465  
Restricted cash 100 100
Intangible asset 120 120
Total assets 12,272 26,319
Current liabilities:    
Accounts payable 1,119 1,404
Accrued expenses and other current liabilities 832 1,251
Lease liability, short term 415  
Total current liabilities 2,366 2,655
Lease liability, long term 51  
Total liabilities 2,417 2,655
Commitments (See Note 10)  
Stockholders' equity:    
Preferred stock, $0.001 par value; 5,000,000 shares authorized Series A Convertible Preferred stock, $0.001 par value; 11,984 shares designated; 0 and 9,856 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively  
Common stock, $0.001 par value; 15,000,000 shares authorized; 1,575,246 and 328,689 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively, and 177 shares to be issued as of December 31, 2018 2  
Additional paid in capital 218,258 212,157
Accumulated deficit (208,363) (188,452)
Accumulated other comprehensive loss (42) (41)
Total stockholders' equity 9,855 23,664
Total liabilities and stockholders' equity $ 12,272 $ 26,319
v3.19.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
COSTS AND EXPENSES:        
Research and development $ 5,052 $ 3,264 $ 12,502 $ 12,501
General and administrative 2,839 2,277 7,592 6,171
Total costs and expenses 7,891 5,541 20,094 18,672
Operating Loss (7,891) (5,541) (20,094) (18,672)
Interest income, net 53 62 183 171
NET LOSS $ (7,838) $ (5,479) $ (19,911) $ (18,501)
Net loss per common share, basic and diluted (in dollars per share) $ (5.69) $ (54.99) $ (23.93) $ (195.51)
Weighted average common shares outstanding, basic and diluted (in shares) 1,377,857 99,640 832,050 94,628
v3.19.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (19,911) $ (18,501)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 21 43
Stock-based compensation 1,098 1,259
Changes in operating assets and liabilities:    
Prepaid expenses and other (508) (149)
Accounts payable (285) (249)
Operating lease liabilities 2  
Accrued expenses and other current liabilities (386) 450
Net cash used in operating activities (19,969) (17,147)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of furniture and fixtures (12) (7)
Net cash used by investing activities (12) (7)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from exercise of warrants 70  
Proceeds, net of $485 and $172 expenses, from sale of common stock 4,904 6,352
Net cash provided by financing activities 4,974 6,352
Effect of currency rate change on cash (3) (10)
Net decrease in cash, cash equivalents and restricted cash (15,010) (10,812)
Cash, cash equivalents and restricted cash beginning of the period 25,134 25,585
Cash, cash equivalents and restricted cash end of period 10,124 $ 14,773
Non cash financing activities:    
Issuance of common stock under employee benefit plan $ 3